09/04/2024 | Press release | Distributed by Public on 09/04/2024 04:31
Item 2.01. |
Completion of Acquisition or Disposition of Assets. |
As previously disclosed, on April 1, 2024, Eiger BioPharmaceuticals, Inc. (the "Company") and its direct subsidiaries filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Northern District of Texas (the "BankruptcyCourt") under the caption In re Eiger BioPharmaceuticals, Inc., et al, Case No. 24-80040(the "Chapter 11 Cases").
Lonafarnib Antiviral Asset Sale
On August 1, 2024, the Company and Eiger InnoTherapeutics, Inc. (the "Purchaser") entered into that certain Lonafarnib Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company's rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain lonafarnib antiviral products for $5.2 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities. At a hearing held on August 20, 2024, the Bankruptcy Court approved the sale of the Company's lonafarnib antiviral asset to the Purchaser.
The sale of the Company's lonafarnib antiviral asset closed on September 3, 2024. Under the terms of the sale, the Purchaser acquired the Company's lonafarnib antiviral asset and will be responsible for its development, manufacture and commercialization.
Peginterferon Lambda Asset Sale
On August 1, 2024, the Company and the Purchaser entered into that certain Lambda Asset Purchase Agreement, pursuant to which the Purchaser agreed to acquire all of the Company's rights, title and interests in, to and under the assets and interests used in the business related to the development, manufacture and commercialization of certain peginterferon lambda-1aproducts for $1.0 million, plus a portion of the cure costs with respect to assigned contracts and the assumption of specified liabilities. At a hearing held on August 20, 2024, the Bankruptcy Court approved the sale of the Company's peginterferon lambda asset to the Purchaser.
The sale of the Company's peginterferon lambda asset closed on September 3, 2024. Under the terms of the sale, the Purchaser acquired the Company's peginterferon lambda asset and will be responsible for its development, manufacture and commercialization.
Cautionary Statements Regarding Trading in the Company's Securities
The Company's securityholders are cautioned that trading in the Company's securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Chapter 11 Cases. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities. In particular, the Company expects that its securityholders could experience a significant or complete loss on their investment, depending on the outcome of the Chapter 11 Cases.